Imipenem monohydrate
产品说明书
 |
同义名 : | 亚胺培南一水物 ;N-Formimidoyl thienamycin monohydrate;MK0787 monohydrate;N-Formimidoyl Thienamycin;Imipenem (hydrate);Imipenem |
| CAS号 : | 74431-23-5 | |
| 货号 : | A103901 | |
| 分子式 : | C12H19N3O5S | |
| 纯度 : | 99%+ | |
| 分子量 : | 317.361 | |
| MDL号 : | MFCD09753321 | |
| 存储条件： |
Pure form Keep in dark place,Inert atmosphere,Store in freezer, under -20°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
H2O: 6 mg/mL(18.91 mM)，配合低频超声，并水浴加热至45℃助溶 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Imipenem (Monohydrate) is the first of a new class of beta-lactam antibiotics, the carbapenems, to be released for clinical use. It has the broadest antibacterial activity of all antibiotics available for systemic use in humans. It is active against streptococci, methicillin-sensitive staphylococci, Neisseria, Haemophilus, anaerobes, and the common aerobic gram-negative nosocomial pathogens including Pseudomonas [3]. For combinations of imipenem and colistin, synergy was observed for the fourteen isolates with imipenem MICs of 16 μg/mL and one isolate with an imipenem MIC of 64 μg/mL[4]. Imipenem/cilastatin is generally well tolerated by adults and children, with local injection site events, gastrointestinal disturbances and dermatological reactions being the most common adverse events[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01381549 | Infections, Urinary Tract | Phase 2 | Terminated(Microbiological fin... 展开 >>dings of resistance on therapy in patients with complicated urinary tract infection) 收起 << | - | United States, California ... 展开 >> GSK Investigational Site Los Angeles, California, United States, 90033 United States, Iowa GSK Investigational Site Council Bluffs, Iowa, United States, 51503 United States, Kansas GSK Investigational Site Topeka, Kansas, United States, 66604 United States, Texas GSK Investigational Site Corsicana, Texas, United States, 75110 Canada, Quebec GSK Investigational Site Chicoutimi, Quebec, Canada, G7H 5H6 GSK Investigational Site Sherbrooke, Quebec, Canada, J1H 5N4 France GSK Investigational Site Suresnes, France, 92151 GSK Investigational Site Toulouse cedex 9, France, 31059 Greece GSK Investigational Site Athens, Greece, 11527 GSK Investigational Site Chaidari, Greece, 12462 GSK Investigational Site Goudi, Athens, Greece, 11527 GSK Investigational Site Thessaloniki, Greece, 56429 Russian Federation GSK Investigational Site Irkutsk, Russian Federation, 664079 GSK Investigational Site Moscow, Russian Federation, 125367 GSK Investigational Site Rostov-on-Don, Russian Federation, 344022 GSK Investigational Site Smolensk, Russian Federation, 214018 GSK Investigational Site St'Petersburg, Russian Federation, 194354 Spain GSK Investigational Site Alicante, Spain, 03010 GSK Investigational Site Elche (Alicante), Spain, 03203 GSK Investigational Site Getafe/Madrid, Spain, 28905 GSK Investigational Site Granada, Spain, 18003 GSK Investigational Site Madrid, Spain, 28040 GSK Investigational Site Murcia, Spain GSK Investigational Site Pama de Mallorca, Spain, 07010 收起 << |
| NCT01381549 | - | Terminated(Microbiological fin... 展开 >>dings of resistance on therapy in patients with complicated urinary tract infection) 收起 << | - | - | |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.15mL 0.63mL 0.32mL |
15.75mL 3.15mL 1.58mL |
31.51mL 6.30mL 3.15mL |
| 参考文献 |
|---|
|
[3]Hellinger WC, Brewer NS. Imipenem. Mayo Clin Proc. 1991;66(10):1074–1081 |